Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A00003453" target="_blank" >RIV/00216208:11120/11:00003453 - isvavai.cz</a>
Alternative codes found
RIV/00064211:_____/11:#0000101
Result on the web
<a href="http://dx.doi.org/10.1200/JCO.2011.37.2623" target="_blank" >http://dx.doi.org/10.1200/JCO.2011.37.2623</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.2011.37.2623" target="_blank" >10.1200/JCO.2011.37.2623</a>
Alternative languages
Result language
angličtina
Original language name
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
Original language description
To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PBC) as first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC). The addition of dulanermin to PC and PCB did not improve outcomes in unselected patients with previously untreated advanced or recurrent NSCLC.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Clinical Oncology
ISSN
0732-183X
e-ISSN
—
Volume of the periodical
29
Issue of the periodical within the volume
33
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
4442-4451
UT code for WoS article
000297257400023
EID of the result in the Scopus database
—